Back to Agenda
Session 4: HTA, Pricing & Reimbursement challenges for ATMPs
Session Chair(s)
Alexander Natz, JD
Secretary General, European Confederation of Pharmaceutical Entrepreneurs, Belgium
How to make sure ATMPS reach patients in Europe? Exchange with experts for concrete solutions to ensure equal access to these transformative therapies! Can innovative pricing models address payer’s uncertainties? Will authorities finally adapt HTA process to the specificities of ATMPs? What does the EU Pharma Strategy imply for ATMPs?
Join us in this session to discuss with experts and fellow stakeholders.
Topics explored in this Session:
- Innovative pricing models as a tool to address uncertainties.
- Implications of the Pharma Strategy on ATMPs.
- HTAs and Payers preparedness for ATMPs.
- Cross-border healthcare and advice harmonisation between Member States.
Speaker(s)
Paolo Morgese, MSc
Head of Public Affairs, Alliance for Regenerative Medicine (ARM), Belgium
Implications of the Pharma Strategy on ATMPs – EU Perspective
Alexander Natz, JD
Secretary General, European Confederation of Pharmaceutical Entrepreneurs, Belgium
Innovative pricing models as a tool to address uncertainties – German perspective
Christian Hill
Chief Executive Officer, MAP Biopharma Limited, United Kingdom
HTA, pricing & Reimbursement approach for ATMPs - UK perspective
Have an account?